Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressan
Background: To evaluate whether the risk of methotrexate (MTX) exposure through skin contamination using parenteral doses of 25 mg warrants special oncology handling precautions during administration. Methods: We conducted a study with six human volunteers deliberately exposed to an entire dose of 25 mg MTX solution on their skin for 30 min. Serum levels of MTX were measured at baseline, 2, 4, 8, 12 and 24 h as well as serum homocysteine at baseline and 24 h after clinical exposure....[Show more]
|Collections||ANU Research Publications|
|Source:||Internal Medicine Journal|
|01_Wong_Potential_for_methotrexate_2009.pdf||786.83 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.